Alkermes (NASDAQ:ALKS) Downgraded by Wall Street Zen to Hold

Alkermes (NASDAQ:ALKS) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other research analysts have also recently weighed in on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. Wolfe Research assumed coverage on shares of Alkermes in a research note on Monday. They issued an “outperform” rating and a $45.00 price objective on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Zacks Research cut shares of Alkermes from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. Finally, Truist Financial increased their price target on shares of Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.07.

Alkermes Trading Down 2.1%

Shares of ALKS opened at $30.10 on Friday. Alkermes has a twelve month low of $25.17 and a twelve month high of $36.32. The firm has a market capitalization of $5.02 billion, a P/E ratio of 21.05 and a beta of 0.49. The firm’s 50-day moving average is $31.54 and its two-hundred day moving average is $30.20.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The company had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. Alkermes’s revenue was down 10.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.05 earnings per share. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Analysts predict that Alkermes will post 1.31 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $33.93, for a total value of $305,370.00. Following the completion of the transaction, the executive vice president directly owned 57,740 shares in the company, valued at approximately $1,959,118.20. This represents a 13.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Shane Cooke sold 61,200 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the transaction, the director owned 103,744 shares in the company, valued at $3,586,430.08. This trade represents a 37.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 148,148 shares of company stock valued at $5,028,378. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Alkermes

Several hedge funds have recently modified their holdings of ALKS. Assetmark Inc. raised its stake in Alkermes by 933.8% during the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 747 shares during the period. Cullen Frost Bankers Inc. acquired a new stake in shares of Alkermes during the 4th quarter worth $28,000. Johnson Financial Group Inc. acquired a new stake in shares of Alkermes during the 3rd quarter worth $31,000. UMB Bank n.a. raised its position in shares of Alkermes by 57.6% in the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock worth $34,000 after buying an additional 446 shares during the period. Finally, Hantz Financial Services Inc. boosted its holdings in Alkermes by 395.6% in the third quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock valued at $37,000 after acquiring an additional 989 shares during the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Key Alkermes News

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analyst optimism — Wells Fargo raised its price target to $43 and kept an overweight stance, signaling bullish analyst conviction that shares have meaningful upside. Wells Fargo raises price target to $43
• Positive Sentiment: RBC still rates ALKS “outperform” and keeps a high price target ($45 after a small cut), indicating continued buy-side support from some sell-side analysts. RBC maintains outperform, lowers PT to $45
• Neutral Sentiment: CEO succession announced — Alkermes disclosed a leadership transition plan; such changes create short-term uncertainty but may be neutral-to-positive over time depending on execution. Alkermes announces CEO succession plan
• Neutral Sentiment: Revenue roughly in line/beat estimates while EPS missed — top-line results were not the primary problem; profitability and EPS dynamics drove the negative reaction. See earnings highlights and call transcript for detail. Q4 2025 earnings highlights
• Negative Sentiment: Earnings miss and downbeat near-term outlook — reported EPS (~$0.29) missed the ~$0.43 consensus and management set FY2026 EPS guidance in negative territory, undercutting the bull case and spurring the sell-off. Shares down after earnings miss
• Negative Sentiment: Market reaction — shares declined sharply on the news and trading volume picked up, reflecting short-term repositioning by investors. Coverage pieces and call transcripts detail investor pushback. ALKS down despite mixed results, leadership change
• Neutral Sentiment: Short-interest reporting in feeds shows inconclusive/zeroed data for February (no actionable signal from that dataset). Short interest note

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.